Therefore, to determine whether these cytokines/chemokines contribute to the reduction in CD226+ expression in CLL, we treated stimulated T cells (anti‐CD3/CD28) with IL‐6, MIP‐1β, and MIP‐1α for 2 days. The gene discussed is IL6; the disease is B-cell chronic lymphocytic leukemia.